The Journal of dermatological treatment最新文献_第2页

Increasing formulary adoption of adalimumab biosimilars and differential cost-sharing in Medicare Part D plans. 在医疗保险D部分计划中增加阿达木单抗生物类似药的处方采用和差异成本分担。

IF 3.9

The Journal of dermatological treatment Pub Date : 2026-12-01 Epub Date: 2026-08-04 DOI: 10.1080/09546634.2026.2709925

Alina S Feng, Wilson Liao

{"title":"Increasing formulary adoption of adalimumab biosimilars and differential cost-sharing in Medicare Part D plans.","authors":"Alina S Feng, Wilson Liao","doi":"10.1080/09546634.2026.2709925","DOIUrl":"https://doi.org/10.1080/09546634.2026.2709925","url":null,"abstract":"Objectives: Adalimumab was among the first biologics to face widespread biosimilar competition following US market entry of multiple adalimumab biosimilars in 2023. However, Medicare Part D formulary adoption of these products and their associated specialty-tier cost-sharing requirements remain unknown.Methods: To evaluate adalimumab biosimilar adoption and associated cost-sharing patterns across Medicare Part D formularies, Centers for Medicare & Medicaid Services (CMS) Medicare Part D Formulary and Plan Benefit Package files were analyzed. Plans were categorized as covering originator adalimumab-only, both originator and biosimilar products (dual coverage), or biosimilars-only.Results: In 2023, all Medicare Part D plans covering adalimumab listed only the originator product. By 2024, 52.5% of plans provided dual coverage, increasing to 79.9% in 2025. Biosimilar-exclusive coverage increased from 8.6% of plans in 2025 to 45.9% in 2026, while originator-only coverage declined to 0.8%. Median specialty-tier coinsurance differed according to coverage strategy. In 2026, median specialty-tier coinsurance was 33% among originator-only plans, 27% among dual-coverage plans, and 25% among biosimilar-only plans.Conclusions: Medicare Part D formularies rapidly included adalimumab biosimilars following market entry, with substantial growth in biosimilar-exclusive coverage by 2026. Specialty tier coinsurance varied by medication coverage type, suggesting that evolving formulary strategies may influence beneficiary cost-sharing requirements.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"37 1","pages":"2709925"},"PeriodicalIF":3.9,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148671897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effectiveness of bimekizumab according to previous biologic exposure in patients with plaque psoriasis: a multicenter real-world study. 比美珠单抗在斑块型银屑病患者中既往生物暴露的有效性：一项多中心现实世界研究

IF 3.9

The Journal of dermatological treatment Pub Date : 2026-12-01 Epub Date: 2026-07-29 DOI: 10.1080/09546634.2026.2707697

Emanuele Trovato, Antonella Di Cesare, Salvatore Panduri, Leonardo Pescitelli, Federica Ricceri, Sofia Lo Conte, Luca Brandini, Aldo Cuccia, Marco Romanelli, Pietro Rubegni, Francesca Prignano

{"title":"Effectiveness of bimekizumab according to previous biologic exposure in patients with plaque psoriasis: a multicenter real-world study.","authors":"Emanuele Trovato, Antonella Di Cesare, Salvatore Panduri, Leonardo Pescitelli, Federica Ricceri, Sofia Lo Conte, Luca Brandini, Aldo Cuccia, Marco Romanelli, Pietro Rubegni, Francesca Prignano","doi":"10.1080/09546634.2026.2707697","DOIUrl":"10.1080/09546634.2026.2707697","url":null,"abstract":"Objectives: Bimekizumab, a dual interleukin (IL)-17A/IL-17F inhibitor, has demonstrated clinical efficacy in clinical trials. However, real-world evidence comparing outcomes according to previous biologic exposure remains limited. We evaluated the effectiveness of bimekizumab in biologic-naïve and biologic-experienced patients with plaque psoriasis, including high-impact body areas.Methods: We retrospectively analyzed 98 patients treated with bimekizumab (23 biologic-naïve, 75 biologic-experienced). Outcomes included Psoriasis Area and Severity Index (PASI), PASI90 and PASI100 response rates, and Physician Global Assessment (PGA) scores for scalp, nail, genital, palmoplantar, and pretibial psoriasis. Biologic-experienced patients were further stratified by the number of prior biologics.Results: Despite higher baseline PASI values (18.04 vs. 13.29; p = 0.021), biologic-naïve patients achieved significantly faster responses. At week 4, PASI reduction (85.5% vs. 62.5%; p < 0.001), PASI90 (50.0% vs. 13.3%; p = 0.001), and PASI100 (50.0% vs. 11.7%; p = 0.001) were significantly higher in biologic-naïve patients. Similar findings were observed in high-impact areas. Differences persisted through week 16 but disappeared from week 24 onward. Nevertheless, biologic-naïve patients maintained numerically higher response rates throughout follow-up. Previous biologic burden did not compromise long-term outcomes.Conclusions: Bimekizumab showed sustained effectiveness regardless of prior biologic exposure. Nevertheless, biologic-naïve patients achieved faster and deeper responses, supporting earlier use of bimekizumab to maximize treatment benefit.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"37 1","pages":"2707697"},"PeriodicalIF":3.9,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148611604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy and safety of a novel 532-nm picosecond Nd:YAG laser for the treatment of freckles in Chinese patients: a randomized, split-face, multicenter, noninferiority trial. 新型532nm皮秒Nd:YAG激光治疗中国患者雀斑的疗效和安全性：一项随机、裂面、多中心、非劣效性试验

IF 3.9

The Journal of dermatological treatment Pub Date : 2026-12-01 Epub Date: 2026-07-20 DOI: 10.1080/09546634.2026.2702775

Yuxi Zhou, Yingqiu Bao, Yu Fu

{"title":"Efficacy and safety of a novel 532-nm picosecond Nd:YAG laser for the treatment of freckles in Chinese patients: a randomized, split-face, multicenter, noninferiority trial.","authors":"Yuxi Zhou, Yingqiu Bao, Yu Fu","doi":"10.1080/09546634.2026.2702775","DOIUrl":"10.1080/09546634.2026.2702775","url":null,"abstract":"Background: The picosecond Nd:YAG laser is a standard treatment for freckles. However, factors such as cost and technology barriers may limit accessibility, necessitating evaluation of alternative systems.Objectives: To evaluate the noninferiority and safety of a novel 532-nm picosecond Nd:YAG laser versus an established system for treating freckles.Methods: In this randomized, evaluator-blinded, split-face trial, 84 participants received a single treatment session. Contralateral facial sides were randomly assigned to the investigational or control device in a 1:1 ratio. The primary endpoint was the response rate at week 8. Secondary endpoints included the cure rate, investigator-assessed improvement, patient satisfaction and procedural tolerability. Safety was assessed by adverse events monitoring.Results: The investigational device demonstrated noninferiority to the control (response rates: 97.6% vs. 97.6%; difference, 0.0%; 95% confidence interval: -3.30% to 3.30%) with comparable cure rates (13.1% vs. 9.5%, p = .527). Participant satisfaction was significantly higher with the investigational device (72.6% vs. 58.3%, p = .001). Treatment duration suggested an association with superior efficacy (OR = 2.07, 95% CI: 1.14-3.76, p = .016). No serious adverse effects occurred.Conclusion: The novel 532-nm picosecond Nd:YAG laser is noninferior to the established system, with comparable short-term efficacy and safety. Further studies are needed to assess long-term safety.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"37 1","pages":"2702775"},"PeriodicalIF":3.9,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148521697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Practical Saudi Guidelines on management of moderate-to-severe psoriasis: 2026 update. 沙特中重度牛皮癣管理实用指南：2026年更新。

IF 3.9

The Journal of dermatological treatment Pub Date : 2026-12-01 Epub Date: 2026-09-07 DOI: 10.1080/09546634.2026.2724623

Mohammed Ibrahim Fatani, Yousef Binamer, Dana Alessa, Hajer Y Almudaiheem, Mohammed Abdulaziz Alajlan, Issam Hamadah, Bedor A Al-Omari, Fahad Alzuriqan, Haifa F Alotaibi, Waleed Alhazzani, Ahmed Aljedai, Maysa Tariq Eshmawi

{"title":"Practical Saudi Guidelines on management of moderate-to-severe psoriasis: 2026 update.","authors":"Mohammed Ibrahim Fatani, Yousef Binamer, Dana Alessa, Hajer Y Almudaiheem, Mohammed Abdulaziz Alajlan, Issam Hamadah, Bedor A Al-Omari, Fahad Alzuriqan, Haifa F Alotaibi, Waleed Alhazzani, Ahmed Aljedai, Maysa Tariq Eshmawi","doi":"10.1080/09546634.2026.2724623","DOIUrl":"10.1080/09546634.2026.2724623","url":null,"abstract":"Background: Psoriasis is a chronic, immune-mediated inflammatory skin disease that affects approximately 5.3% of the population in the Kingdom of Saudi Arabia (KSA). Thus, we aim to develop updated evidence-based clinical practice guidelines for the management of adults and pediatric patients with moderate-to-severe plaque psoriasis in the KSA.Methods: These guidelines followed the \"Grading of Recommendations, Assessment, Development, and Evaluation\" (GRADE) methodology. We conducted a systematic literature review of PubMed, EMBASE, and the Cochrane Library for high-quality evidence published between 2020 and 2026. The panel developed 31 PICO questions that address key treatment considerations for moderate-to-severe psoriasis.Results: We established 27 evidence-based recommendations and 4 good-practice statements addressing key aspects of moderate-to-severe psoriasis management. These guidelines strongly recommend adopting the Psoriasis Area and Severity Index (PASI) 90 as the primary treatment goal over PASI 75. For adult patients, the guidelines recommend biologic therapies, including interleukin (IL)-17 inhibitors, IL-23 inhibitors, IL-12/23 inhibitors, and tumor necrosis factor (TNF)-α inhibitors, for better disease control. For pediatric patients, the guidelines recommend early initiation of biologic therapy, with etanercept, secukinumab, ixekizumab, and adalimumab as preferred options.Conclusion: These Saudi national guidelines offer a comprehensive, evidence-based framework for managing moderate-to-severe psoriasis in adults and pediatric patients.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"37 1","pages":"2724623"},"PeriodicalIF":3.9,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148901814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-world clinical experience with ruxolitinib cream versus systemic therapies in patients with moderate atopic dermatitis in the United States. 美国中度特应性皮炎患者鲁索利替尼乳膏与全身治疗的真实临床经验

IF 3.9

The Journal of dermatological treatment Pub Date : 2026-12-01 Epub Date: 2026-09-07 DOI: 10.1080/09546634.2026.2698965

Jinan Liu, Oliver Howell, James Piercy, Peter Anderson, Daniel Sturm

{"title":"Real-world clinical experience with ruxolitinib cream versus systemic therapies in patients with moderate atopic dermatitis in the United States.","authors":"Jinan Liu, Oliver Howell, James Piercy, Peter Anderson, Daniel Sturm","doi":"10.1080/09546634.2026.2698965","DOIUrl":"https://doi.org/10.1080/09546634.2026.2698965","url":null,"abstract":"Purpose: Ruxolitinib cream (Janus kinase [JAK]1/JAK2 inhibitor) was effective and well tolerated in clinical trials of patients with atopic dermatitis (AD). We examined real-world outcomes among patients with moderate AD treated with ruxolitinib cream or systemic therapies.Methods: Physician-reported data for adults with moderate AD (physician assessed at current treatment initiation) from the Adelphi AD Disease Specific Programme™ (August 2022-March 2023) were analyzed descriptively. Patients treated with ruxolitinib cream, traditional systemic immunosuppressants, oral JAK inhibitors, or biologics comprised 4 mutually exclusive cohorts.Results: Among 619 patients (mean age, 39.1 y; 50% female; 79% White), mean affected body surface area (BSA) was reduced from treatment initiation by 49% with ruxolitinib cream, 35% with systemic immunosuppressants, 61% with oral JAK inhibitors, and 55% with biologics. Nearly half of patients (48.4%) had reduced physician-reported disease severity with ruxolitinib cream versus 6.3%, 51.5%, and 46.4% with systemic immunosuppressants, oral JAK inhibitors, and biologics, respectively. Results were similar among patients with baseline affected BSA ≤20%.Conclusions: Physician-reported outcomes show that ruxolitinib cream monotherapy substantially reduced the extent and severity of moderate AD, suggesting that it provides an effective topical treatment option in these specific populations.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"37 1","pages":"2698965"},"PeriodicalIF":3.9,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148901869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association of a Han Chinese urticaria-derived polygenic risk score with chronic spontaneous urticaria susceptibility and advanced systemic treatment use. 汉族荨麻疹衍生的多基因风险评分与慢性自发性荨麻疹易感性和晚期全身治疗使用的关系

IF 3.9

The Journal of dermatological treatment Pub Date : 2026-12-01 Epub Date: 2026-09-30 DOI: 10.1080/09546634.2026.2737487

Yun-Wen Chen, Yi-Ming Chen, Kuo-Tung Tang, Heh-Shiang Sheu, Wen-Nan Huang, I-Chieh Chen

{"title":"Association of a Han Chinese urticaria-derived polygenic risk score with chronic spontaneous urticaria susceptibility and advanced systemic treatment use.","authors":"Yun-Wen Chen, Yi-Ming Chen, Kuo-Tung Tang, Heh-Shiang Sheu, Wen-Nan Huang, I-Chieh Chen","doi":"10.1080/09546634.2026.2737487","DOIUrl":"https://doi.org/10.1080/09546634.2026.2737487","url":null,"abstract":"Background: Chronic spontaneous urticaria (CSU) is a heterogeneous mast cell-driven disease with variable treatment needs, but the clinical relevance of Han Chinese urticaria-derived polygenic risk scores (PRSs) remains unclear.Objective: To evaluate the associations between Han Chinese urticaria-derived PRSs, CSU susceptibility, and advanced systemic treatment use.Methods: We conducted a retrospective case-control study using Taiwan Precision Medicine Initiative participants at Taichung Veterans General Hospital. CSU cases and matched controls were identified using diagnostic codes and electronic medical records. Five urticaria-derived PRS models were evaluated using receiver operating characteristic curves (ROC). The best-performing PRS was categorized into quartiles, and logistic regression assessed associations with CSU susceptibility and advanced systemic treatment use.Results: The study included 4,676 patients with CSU and 18,704 matched controls. The Lassosum-based urticaria-derived PRS demonstrated the highest area under the ROC curve. Higher PRS quartiles were associated with increased CSU susceptibility, especially Q4. Among 4,550 patients with CSU and available PRS data, higher PRS quartiles were associated with advanced systemic treatment use, with sex-stratified differences observed.Conclusions: A Han Chinese urticaria-derived PRS was associated with CSU susceptibility and advanced systemic treatment use, supporting its potential role as an adjunctive genetic risk-stratification marker in CSU.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"37 1","pages":"2737487"},"PeriodicalIF":3.9,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149083534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Treatment response to systemic therapies in pediatric-onset versus adult-onset psoriasis: a longitudinal real-world study. 儿科发病与成人发病牛皮癣的全身治疗反应：一项真实世界的纵向研究。

IF 3.9

The Journal of dermatological treatment Pub Date : 2026-12-01 Epub Date: 2026-09-23 DOI: 10.1080/09546634.2026.2734961

Siqi Li, Yuxiong Jiang, Didaer Muheyati, Yuanwenke Zhang, Min Dai, Qian Yu, Dawei Huang, Yu Wang, Qian Yu, Yuling Shi

{"title":"Treatment response to systemic therapies in pediatric-onset versus adult-onset psoriasis: a longitudinal real-world study.","authors":"Siqi Li, Yuxiong Jiang, Didaer Muheyati, Yuanwenke Zhang, Min Dai, Qian Yu, Dawei Huang, Yu Wang, Qian Yu, Yuling Shi","doi":"10.1080/09546634.2026.2734961","DOIUrl":"https://doi.org/10.1080/09546634.2026.2734961","url":null,"abstract":"Background: Psoriasis may present with onset in childhood or adulthood, reflecting distinct clinical patterns. Whether treatment response differs between these groups remains unclear, particularly across systemic therapies in real-world settings.Objectives: To compare longitudinal treatment responses between patients with pediatric-onset psoriasis (POPPs) and patients with adult-onset psoriasis (AOPPs) across systemic therapies in real-world practice.Methods: Psoriasis patients receiving interleukin (IL)-17 inhibitors, IL-23 or IL-12/23 inhibitors, methotrexate, or phototherapy were included. Primary outcomes were Psoriasis Area and Severity Index (PASI) 90 and Dermatology Life Quality Index (DLQI) 0/1 at 1, 2, 3, and 6 months. Associations between onset group and treatment outcomes were assessed using generalized estimating equation (GEE) models with adjustment for potential confounders.Results: Among 1873 patients, 576 received IL-17 inhibitors, POPPs had higher PASI90 rates at 1-6 months (26.1%-62.2% vs. 14.6%-51.2%) and higher DLQI 0/1 response rates (30.6%-45.0% vs. 20.3%-40.0%) than AOPPs. Multivariable GEE analyses further demonstrated that, compared with POPPs, AOPPs had lower odds of achieving PASI90 (adjusted odds ratios 0.62, 95% confidence interval 0.42-0.89; p = .011). No significant differences were shown among patients treated with IL-23 or IL-12/23 inhibitors, methotrexate, or phototherapy.Conclusions: Pediatric-onset psoriasis was associated with improved clinical outcomes during IL-17 inhibitor therapy. Further comparative-effectiveness studies are warranted to determine whether onset pattern may contribute to individualized treatment selection.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"37 1","pages":"2734961"},"PeriodicalIF":3.9,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149026825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Letter to the Editor - Active surveillance for basal cell carcinoma-the case for structured, risk-stratified follow-up. 致编辑的信——主动监测基底细胞癌——结构化、风险分层随访的案例。

IF 3.9

The Journal of dermatological treatment Pub Date : 2026-12-01 Epub Date: 2026-07-17 DOI: 10.1080/09546634.2026.2702773

Viren Mehta, Kanika Bhatia

引用次数: 0

A cross-sectional analysis of topical steroid phobia and observable side effects in Thai psoriasis patients. 泰国银屑病患者局部类固醇恐惧症和可观察到的副作用的横断面分析。

IF 3.9

The Journal of dermatological treatment Pub Date : 2026-12-01 Epub Date: 2026-10-15 DOI: 10.1080/09546634.2026.2748079

Pimmada Piemmongkolchai, Chawengsak Khamkaen, Thanakorn Woramongkol, Kanokvalai Kulthanan, Chanisada Wongpraparut, Narumol Silpa-Archa, Chayada Chaiyabutr, Charussri Leeyaphan

{"title":"A cross-sectional analysis of topical steroid phobia and observable side effects in Thai psoriasis patients.","authors":"Pimmada Piemmongkolchai, Chawengsak Khamkaen, Thanakorn Woramongkol, Kanokvalai Kulthanan, Chanisada Wongpraparut, Narumol Silpa-Archa, Chayada Chaiyabutr, Charussri Leeyaphan","doi":"10.1080/09546634.2026.2748079","DOIUrl":"https://doi.org/10.1080/09546634.2026.2748079","url":null,"abstract":"Background: Steroid phobia impairs adherence to topical corticosteroids (TCS) and undermines psoriasis management, yet remains understudied in adult Thai patients.Objectives: To quantify TCS phobia using the TOPICOP scale in Thai adults with psoriasis and identify associated factors.Methods: A cross-sectional survey at Siriraj Hospital enrolled 150 adults with psoriasis and TCS experience, who completed the validated Thai TOPICOP scale.Results: Of 150 participants, 81 (54.0%) were female, median age 52 years (IQR 35.0-62.3). Mean TOPICOP score was 17.1 ± 5.3/36 (47.5% ± 14.7%). Forty percent reported explicit fear of TCS. Dermatologist-confirmed side effects, most commonly skin atrophy, were present in 50.0% and associated with higher TOPICOP scores (18.1 ± 4.3 vs. 16.0 ± 6.0; p = 0.016). Facial involvement was also associated with higher scores (18.1 ± 5.0 vs. 16.3 ± 5.4; p = 0.032). TOPICOP scores correlated positively with DLQI (r = 0.175; p = 0.030) and educational level (r = 0.240; p = 0.003).Conclusions: TCS phobia is prevalent among Thai adults with psoriasis, more pronounced with facial involvement, prior side-effect experience, and quality-of-life impairment. Individualized counseling is recommended to promote safe TCS use.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"37 1","pages":"2748079"},"PeriodicalIF":3.9,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149198462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Dermatologic indications for microwave-induced local hyperthermia. 微波局部热疗的皮肤指征。

IF 3.9

The Journal of dermatological treatment Pub Date : 2026-12-01 Epub Date: 2026-01-06 DOI: 10.1080/09546634.2025.2605619

Aditya K Gupta, Elizabeth A Cooper, Menno T W Gaastra, Michael H Gold

{"title":"Dermatologic indications for microwave-induced local hyperthermia.","authors":"Aditya K Gupta, Elizabeth A Cooper, Menno T W Gaastra, Michael H Gold","doi":"10.1080/09546634.2025.2605619","DOIUrl":"https://doi.org/10.1080/09546634.2025.2605619","url":null,"abstract":"Objectives: The potential utility of a novel microwave device for the treatment of a variety of superficial dermatologic indications is reviewed.Materials and methods: The Swift® microwave system applies low-dose microwave energy (8 GHz) noninvasively using a precision applicator to directly target lesional tissue, while modulating power setting and application time to maintain patient comfort during heat application. The device has been approved for general dermatology use, with some models labeled more-specifically for HPV-associated lesions and actinic keratosis. New case treatment data and published case reports were reviewed for viral skin infection, fungal nail infection, nodular cystic acne, neoplastic skin lesions, hidradenitis suppurativa (HS), and intractable plantar keratosis (IPK).Results: Case reports demonstrate preliminary efficacy of microwave hyperthermia in viral skin infection, fungal nail infection, nodular cystic acne, and neoplastic skin lesions, with few reported adverse events. Microwaves additionally provided good pain control for the reviewed cases of HS and IPK.Conclusions: The data support a possible role for the microwave device in the studied indications. Microwave treatment may be more tolerable for patients than cryotherapy or laser comparators. More systematic investigation of microwave hyperthermia is warranted to better define optimum dosing regimens and efficacy, as well as a wider safety profile.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"37 1","pages":"2605619"},"PeriodicalIF":3.9,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145914448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0